[en] SUMMARY: This analysis was conducted to assess the effect of high versus lower doses of ibandronate on nonvertebral fractures. The results were adjusted for clinical fracture, age, and bone density. The treatment effect was dose-dependent. Higher doses of ibandronate significantly reduced the risk of nonvertebral fractures more effectively compared with lower doses. INTRODUCTION: The objective of this study was to assess the efficacy of different doses of ibandronate on nonvertebral fractures in a pooled analysis. METHODS: Eight randomized trials of ibandronate were reviewed for inclusion. Alternative definitions of high versus low doses based on annual cumulative exposure (ACE) were explored. A time-to-event analysis was conducted using Kaplan-Meier methodology. Hazard ratios (HR) were derived using Cox regression and adjusted for covariates. RESULTS: Combining higher ACE doses of > or = 10.8 mg (150 mg once monthly, 3 mg i.v. quarterly, and 2 mg i.v. every 2 months) versus ACE doses of 5.5 mg, from two trials, resulted in an HR 0.62 (95% CI 0.396-0.974, p = 0.038). There was a dose-response trend with increasing ACE doses (7.2-12 mg) versus ACE of 5.5 mg. CONCLUSIONS: A dose-response effect on nonvertebral fractures was observed when comparing high with low ACE doses. A significant reduction in nonvertebral fractures was noted when pooling data from trials using ACE doses of > or = 10.8 mg versus ACE < or = 7.2 mg; and with ACE > or = 10.8 mg versus ACE of 5.5 mg (38% reduction). Higher ibandronate dose levels (150 mg monthly or 3 mg i.v. quarterly) significantly reduced nonvertebral fracture risk in postmenopausal women.
Disciplines :
General & internal medicine
Author, co-author :
Cranney, Ann; Ottawa Health Research Institute
Wells, G. A.
Yetisir, E.
Adami, S.
Cooper, C.
Delmas, P. D.
Miller, P. D.
Papapoulos, S.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
CH Chesnut III A Skag C Christiansen R Recker JA Stakkestad A Hoiseth 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 8 1241 1249
R Recker JA Stakkestad CH Chesnut III C Christiansen A Skag A Hoiseth 2004 Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis Bone 34 5 890 899
PD Miller MR McClung L Macovei JA Stakkestad M Luckey B Bonvoisin 2005 Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res 20 8 1315 1322
PD Delmas S Adami C Strugala JA Stakkestad JY Reginster D Felsenberg 2006 Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study Arthritis Rheum 54 6 1838 1846
P Ravn G Neugebauer C Christiansen 2002 Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis Bone 30 1 320 324
S Adami D Felsenberg C Christiansen J Robinson RS Lorenc P Mahoney 2004 Efficacy and safety of ibandronate given by intravenous injection once every 3 months Bone 34 5 881 889
BJ Riis J Ise T von Stein Y Bagger C Christiansen 2001 Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis J Bone Miner Res 16 10 1871 1878
D Thiebaud P Burckhardt H Kriegbaum H Huss H Mulder JR Juttmann 1997 Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis Am J Med 103 4 298 307
PD Delmas RR Recker CH Chesnut III A Skag JA Stakkestad R Emkey 2004 Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study Osteoporos Int 15 10 792 798
JY Reginster S Adami P Lakatos M Greenwald JJ Stepan SL Silverman 2006 Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study Ann Rheum Dis 65 5 654 661
J Barrett E Worth F Bauss S Epstein 2004 Ibandronate: a clinical pharmacological and pharmacokinetic update J Clin Pharm 44 9 951 965
SC Cremers G Pillai SE Papapoulos 2005 Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimization of intermittent therapy for osteoporosis Clin Pharmacokinet 44 6 551 570
SE Papapoulos RC Schimmer 2007 Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate Ann Rheum Dis 66 7 853 858
JT Harrington LG Ste-Marie ML Brandi R Civitelli P Fardellone A Grauer 2004 Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis Calcif Tissue Int 74 2 129 135
SE Papapoulos SA Quandt UA Liberman MC Hochberg DE Thompson 2005 Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women Osteoporos Int 16 5 468 474
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.